Karyopharm Therapeutics Inc.
KPTI
$8.38
-$0.17-1.99%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -22.63% | 16.12% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -22.63% | 16.12% | |||
| Cost of Revenue | -10.74% | -3.49% | |||
| Gross Profit | -56.72% | 178.41% | |||
| SG&A Expenses | -14.41% | -6.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.39% | -4.90% | |||
| Operating Income | -17.24% | 37.59% | |||
| Income Before Tax | -209.02% | 11.07% | |||
| Income Tax Expenses | -297.06% | -15.00% | |||
| Earnings from Continuing Operations | -208.50% | 11.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -208.50% | 11.07% | |||
| EBIT | -17.24% | 37.59% | |||
| EBITDA | -18.05% | 37.89% | |||
| EPS Basic | -49.38% | 11.58% | |||
| Normalized Basic EPS | 41.62% | 11.57% | |||
| EPS Diluted | -49.41% | 11.58% | |||
| Normalized Diluted EPS | 41.62% | 11.57% | |||
| Average Basic Shares Outstanding | 106.53% | 0.57% | |||
| Average Diluted Shares Outstanding | 106.53% | 0.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||